http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2000510326-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-108 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0368 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate | 1997-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2000-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2000510326-A |
| titleOfInvention | Anti-apoptotic gene therapy for transplantation and inflammatory conditions |
| abstract | (57) Abstract: A method for reducing the sensitivity of a mammal, especially an endothelial cell, to a inflammatory or other immunological activating stimulator by genetically modifying the cell, wherein the NF is expressed in the cell or its progenitor cells. By inserting a DNA encoding an anti-apoptotic polypeptide capable of inhibiting -κB and expressing the protein, it is confirmed that NF-κB in cells is substantially inhibited in the presence of a cell activation stimulating factor. Including methods are described. Suitable polypeptides are selected from those having a containing homologs and truncated forms of the native protein, mammals A20, BCL-2, BCL- X L (MCL-1) or A1 protein activity. BCL-2, BCL-X L or A1 active polypeptide can also be used as heterodimers with another anti-apoptotic polypeptide homodimeric or BCL group. The method may be performed in vivo or ex vivo or in vitro and is particularly useful for allogeneic or especially xenotransplantation and for treating systemic or local inflammatory conditions. The ability to produce non-human transgenic or somatic recombinant mammals that express the polypeptide in a manner that can be regulated by endothelial cells allows the cells and tissues or organs containing the cells to be transplanted into mammalian recipients. Is obtained. |
| priorityDate | 1996-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 317.